Background {#Sec1}
==========

Hepatocellular carcinoma (HCC) is one of the most common malignancies and a leading cause of cancer-related mortality worldwide \[[@CR1], [@CR2]\]. The risk factors for HCC, such as hepatitis B virus or hepatitis C virus infection, are well documented. Tumor metastasis are the main cause of death in patients with HCC. Recent studies suggest that tumor metastasis is a complex process affected by multiple procedures and multiple mediators in human cancers \[[@CR3], [@CR4]\]. However, the underlying molecular mechanism in HCC metastasis still remains poorly understood. Tumor metastasis may be affected by many intracellular signaling molecules and extracellular components, such as cytokines, neurotransmitters or the extracellular matrix \[[@CR5], [@CR6]\].

The Hippo pathway is an evolutionarily conserved signaling module that plays critical roles in liver size control and tumorigenesis \[[@CR7], [@CR8]\]. In mammals, the Hippo pathway is a kinase cascade, wherein Macrophage Stimulating 1/2 (MST1/2), in a complex with its regulatory protein Salvador Family WW Domain Containing Protein 1 (SAV1), phosphorylates and activates Large Tumor Suppressor Kinase 1/2 (LATS1/2). Yes-Associated Protein (YAP)/ Tafazzin (TAZ) can be phosphorylated and inactivated by active LATS1/2; when it is restrained in the cytoplasm, it loses its transcriptional activation of pro-proliferation and anti-apoptosis genes. The Hippo pathway can be activated by many biological factors including contact inhibition, mechanical strain on the cell, cell polarity/adhesion molecules, other signaling pathways and cellular metabolic status \[[@CR9]\]. Cytokinesis failure has recently been shown to trigger the Hippo pathway \[[@CR10]\]. Nevertheless, the link between LIM domain only 3 (LMO3) and the Hippo pathway has not been reported.

The LMO protein family includes four members: LMO1, LMO2, LMO3 and LMO4. Although LMO proteins lack DNA binding activity, some reports indicate that they are involved in the transcriptional regulation of target genes in collaboration with other transcription factors. Genetic analyses indicate that LMO1 and LMO2 contribute to the genesis of immature and aggressive T-cell leukemia \[[@CR11]\]. LMO4 was implicated in the development of breast cancer \[[@CR12], [@CR13]\]. LMO3 was reported to form a complex with neuronal-specific basic helix-loop-helix (bHLH) transcription factor Helix-Loop-Helix protein 2 (HEN2), which was also expressed at higher levels in unfavorable neuroblastoma than in the favorable type. Moreover, LMO3 has been reported to play important roles in some types of cancer, including neuroblastoma \[[@CR14], [@CR15]\] and lung cancer \[[@CR16], [@CR17]\].

In this research, we found that the expression of LMO3 was significantly upregulated in HCC tissues. LMO3 expression was closely related to clinicopathological findings or patient prognoses. Knockdown of LMO3 suppresses the invasion, metastasis and anoikis inhibition of HCC cells. Further, the effects of LMO3 on the biological behaviors of HCC cells are dependent on the suppression of Hippo signaling.

Methods {#Sec2}
=======

Cell culture {#Sec3}
------------

Human HCC cell lines, including HCCLM3, HepG2, Huh-7, MHCC-97H, MHCC-97 L, SK-Hep1, SMMC-7721, SNU-423 and SNU-449 were purchased from Cell Bank of the Chinese Academy of Sciences. Dulbecco's modified Eagle's medium (DMEM) contained 10% (*v*/v) fetal calf serum (FCS) and 1% antibiotics was used. Cells were incubated at 37 °C in a humidified incubator under 5% CO~2~ condition.

Clinical samples {#Sec4}
----------------

Clinical human HCC (16 cases) and corresponding non-cancerous liver (CNL) tissues (12 cases), in which 12 cases were paired, were obtained from Shanghai University of Traditional Chinese Medicine Affiliated Shuguang Hospital. Additionally, Human tissue microarray contained 180 cases of HCC samples was bought from Alenabio.

Ethics, consent and permissions {#Sec5}
-------------------------------

All human samples were obtained with informed consent. The protocols were approved by the ethical review committee of the World Health Organization Collaborating Center for Research in Human Production (authorized by the Shanghai Municipal Government).

Quantitative real-time PCR {#Sec6}
--------------------------

Total RNA was extracted by Trizol (Takara), and reversely transcribed by PrimeScript RT-PCR kit (Perfect Real Time). Quantitative real-time PCR analyses were performed by SYBR *Premix Ex Taq* (Takara) on a 7500 real-time PCR system (Applied Biosystems), with recommended thermal cycling settings: one initial cycle at 95 °C for 30 s followed by 40 cycles of 5 s at 95 °C and 31 s at 60 °C. Primer sequences used for human LMO3, CTGF, ANKRD1 and CYR61 detection were shown in Additional file [1](#MOESM1){ref-type="media"}: Table S1.

Immunohistochemical staining {#Sec7}
----------------------------

All tissue samples were fixed in phosphate-buffered neutral formalin, embedded in paraffin, and cut into 5 μm thick sections. The sections were deparaffinized and rehydrated, incubated with 0.3% hydrogen peroxide/phosphate-buffered saline for 30 min, and blocked with 10% BSA (Sangon). The antibody for LMO3 (Abcam) was used to incubate the slides at 4 °C overnight with optimal dilution. HRP (rabbit) second antibody (Huabio) was used to incubate above slides at room temperature for 1 h. The slides were labeled with DAB substrate liquid (Thermo Scientific) and counterstained by hematoxylin. All the sections were photographed with a microscope (Carl Zeiss). Scoring was designated according to the ratio and intensity of positive-staining cells: 0--5% scored 0; 6--40% scored 1; 41--70% scored 2; more than 70% scored 3. The final score was defined as low or high expression group as follows: score 0--1, low expression, score 2--3, high expression. All scores were determined independently by more than two senior pathologists in a blinded manner.

Western blotting and GTPase pull-down assays {#Sec8}
--------------------------------------------

Cells were lysed in lysis buffer. Then the proteins were separated by SDS-PAGE under reducing condition. The membranes were blocked in phosphate-buffered saline/Tween-20 containing 5% BSA, then incubated by the antibodies for LMO3 (Abcam), phospho-YAP (Cell Signaling), total-YAP (Cell Signaling), phospho-LATS1 (Cell Signaling), total-LATS1 (Cell Signaling), GAPDH (Huabio) and species-specific secondary antibodies separately. The membranes were detected by Odyssey imaging system (LI-COR). GTPase pull-down assays were performed according to standard procedures as described \[[@CR18]\].

siRNA or shRNA transfection {#Sec9}
---------------------------

Small interfering RNAs duplexes for LMO3 used in this study was produced by Genepharma. Transfection steps were performed according to the manufacture's protocols. The sequences of siRNA were designed as: si-LMO3--1: F: GGACUACGAGGAAGGUUUAdTdT, R: UAAACCUUCCUCGUAGUCCdTdT; si-LMO3--2: F: GCUGCAACCGAAAGAUCAAdTdT, R: UUGAUCUUUCGGUUGCAGCdTdT. Further, shRNA sequence was designed as: sh-LMO3: F: GATCCGTACACTAAAGCTAATCTT ATCTTCCTGTCAGAATAAGATTAGCTTTAGTGTACTTTTTG, R: AATTCAAAAAGTACACTAAAGCTAATCTTATTCTGACAGGAAGATAAGATTAGCTTTAGTGTACG. The structure of pGreenPuro used for shRNA and vector construction was shown in Additional file [2](#MOESM2){ref-type="media"}: Figure S2.

rLMO3 protein and inhibitors {#Sec10}
----------------------------

Recombinant LMO3 (rLMO3) protein was purchased from Abnova. The inhibitor of Hippo (Verteporfin and Peptide 17) were purchased from Selleck.

In vitro invasion assay {#Sec11}
-----------------------

MHCC-97H or SMMC-7721 cells were detached by 0.25% trypsin/0.01% EDTA in 1 × PBS and resuspended in serum-free DMEM medium. 2 × 10^4^ cells in 100 μl were added into matrigel (BD)-coated inserts (Millipore) seated on the 24-well plate. Then DMEM medium contained 5% FBS was added into the bottom chamber. After the cells were incubated at 37 °C for 48 h, filters were fixed and stained with 0.1% (*w*/*v*) Crystal Violet. Non-invading cells were removed firstly, and invading cells were counted under a microscope at a magnification of 400×. About 3 grids per field were counted. All of the experiments were repeated twice.

Anoikis assays {#Sec12}
--------------

5 × 10^5^ MHCC-97H or SMMC-7721 cells were cultured on poly-HEMA treated 12-well plates at 37 °C for 48 h. Then the adherent cells were detached and harvested in complete DMEM medium and centrifuged at 1000 rpm/5 min. The cells were washed with 1 × PBS and incubated with 100 μl binding buffer containing 3.5 μl Annexin V and 3.5 μl propidium iodide (PI) at room temperature for 15 min. All of the cells were analyzed by flow cytometry (BD).

Edu assay {#Sec13}
---------

1 × 10^6^ MHCC-97H or SMMC-7721 cells were seeded into 6-well plates. 50 μM of Edu from Edu Apollo^®^ 488 In Vitro Flow Cytometry Kit (RiBoBio) was added into the plates 2 h before harvesting the cells. Cells were collected and centrifuged at 1000 rpm/5 min, and supernatant was removed. For fixation, 4% paraformaldehyde was added into the cells and incubated for 15 min, and washed once by 1 × PBS. Then cells were resuspended in Tris buffer saline with 0.5% Triton X-100 and incubated for 10 min, and washed again with 1 × PBS. Amounts of 500 μl staining solution with Apollo^®^ 488 fluorescent azide was added into cells, incubated for 10 min, and then rinsed twice with Tris buffer saline with 0.5% Triton X-100. All of the cells were analyzed by flow cytometry (BD).

In vivo metastasis assays {#Sec14}
-------------------------

2 × 10^6^ SMMC-7721 cells infected with sh-LMO3 or control, were detached and suspended in 30 μl serum-free DMEM/matrigel (1:1) for each BALB/c-nu/nu mouse. Through a 1 cm transverse incision in the upper abdomen under anesthesia, each mouse (6 weeks, male, 10 in each group) was orthotopically inoculated in the left hepatic lobe with a microsyringe. Meanwhile, 1 × 10^6^ SMMC-7721 cells infected with sh-LMO3 or control were injected intravenously into nude mice (6 in each group). Mice were sacrificed after 6 weeks. The livers and lungs were dissected, fixed with phosphate-buffered neutral formalin and prepared for standard histological examination. All of mice were manipulated and housed according to protocols approved by the Shanghai University of Traditional Chinese Medicine Animal Care Commission. All animals received humane care according to the criteria outlined in the "Guide for the Care and Use of Laboratory Animals" prepared by the National Academy of Sciences and published by the National Institutes of Health.

Co-immunoprecipitation {#Sec15}
----------------------

For intracellular immunoprecipitation, Huh-7 cell lysates transfected with HA-tagged LMO3 or vector control were subjected to immunoprecipitation with anti-HA monoclonal antibody (Millipore) or control IgG. Then the immunoblotting with anti-LATS1 or YAP antibodies was performed.

Statistical analysis {#Sec16}
--------------------

Values are expressed as the mean ± standard error of the mean. Statistical analyses were performed using SPSS 16.0 for windows. Survival time was analyzed with the Kaplan-Meier method. The association between LMO3 expression and the clinicopathological features of HCC patients was evaluated using Pearson's Chi-square test. One-way analysis of variance was used for comparison between groups. *P* \< 0.05 was considered to indicate a statistically significant difference.

Results {#Sec17}
=======

LMO3 is upregulated in HCC, and closely related with the clinicopathological findings and patient prognoses {#Sec18}
-----------------------------------------------------------------------------------------------------------

To investigate the expression level of LMO3 in HCC tissues, we collected 16 cases HCC and 12 cases CNL tissues. Through Quantitative real-time PCR, we found that the expression of LMO3 was significantly upregulated in HCC tissues (Fig. [1a](#Fig1){ref-type="fig"}). In 12 paired HCC and CNL tissues, the mRNA expression of LMO3 was found to be significantly upregulated in HCC tissues (Fig. [1b](#Fig1){ref-type="fig"}). Furthermore, in 5 paired HCC and CNL tissues, the protein expression of LMO3 was also found to be significantly upregulated in HCC tissues (Fig. [1c](#Fig1){ref-type="fig"}).Fig. 1LMO3 expression is upregulated in HCC and closely related with clinicopathological findings or patient prognoses. **a** The mRNA expression level of LMO3 in 16 cases HCC and 12 cases corresponding noncancerous liver (CNL) tissues. **b** The mRNA expression level of LMO3 in 12 paired HCC and CNL tissues. **c** The protein expression level of LMO3 in 5 paired HCC and CNL tissues. \*\**P* \< 0.01. **d** The immunohistochemical staining of LMO3 in HCC and CNL tissues. Scale bars: 10 μm. **e** By analyzing HCC tissue microarray (*n* = 180), the expression of LMO3 was found to be upregulated in 75.40% HCC tissues. **f** The immunohistochemical staining of LMO3 in HCC, thrombus, CNL and normal liver tissues. Scale bars: 5 μm. **g** Western blotting analysis of LMO3 expression in HCC, thrombus, CNL and normal liver tissues. GAPDH was used as a loading control. **h** and **i** Kaplan-Meier analysis of overall survival (OS) (**f**, *P* = 0.019) and disease-free survival (DFS) (**g**, *P* = 0.179) for the expression of LMO3

Then we used an HCC tissue microarray (*n* = 180) to detect the correlation between LMO3 expression and clinicopathological findings and patient prognoses (Additional file [3](#MOESM3){ref-type="media"}: Table S2). We found that the expression of LMO3 was upregulated in 75.40% HCC tissues (Fig. [1e](#Fig1){ref-type="fig"}). The upregulated LMO3 expression in HCC tissues was further confirmed by immunohistochemical staining (Fig. [1d](#Fig1){ref-type="fig"}). Also, we found that the expression of LMO3 was closely related to patient tumor encapsulation, thrombus, vascular invasion and TNM stage (Table [1](#Tab1){ref-type="table"}). To investigate the relevance of LMO3 with HCC metastasis, we collected HCC, tumor thrombus, CNL and normal liver tissues from the same patients and detected LMO3 expression in these tissues. Through immunohistochemical staining and western blotting, we found that LMO3 expression was higher in the HCC and tumor thrombus tissues, and lower in the CNL and normal liver tissues (Fig. [1f](#Fig1){ref-type="fig"}, [g](#Fig1){ref-type="fig"}). Additionally, we found that the high expression of LMO3 was positively correlated with poor overall patient survival (OS) (*P* = 0.019), while it was not correlated with patient disease-free survival (DFS) (*P* = 0.179) (Fig. [1h](#Fig1){ref-type="fig"}, [i](#Fig1){ref-type="fig"}).Table 1Correlation of the clinicopathological findings with LMO3 expressionVariableLMO3 (n)HighLow*P*Age≤50 years28650.382\> 50 years3562GenderFemale7200.389Male56107Hepatitis historyYes531160.263No1011Gamma-glutamytransferase≤50(U/L)22500.605\> 50(U/L)4077Alpha-fetoprotein≤20 ng/mL18490.185\> 20 ng/mL4477Glu≤7 mmol/L6110.793\> 7 mmol/L55116Tumor multiplicitySingle491110.087Multiple1416Tumor sateliteYes19390.938No4488**\*Tumor encapsulationIncomplete26340.029Complete3593\*Tumor thrombusYes2218\< 0.001No41109**Tumor differentiationI210.458II2349III3876**\*Vascular invasionYes24270.014No39100**Tumor size≤5 cm29710.199\> 5 cm3456**\*TNM stageI31860.020II715III2525**Pearson's χ^2^ test was used. The bolding stands for the *P*-values with significant differences

Knockdown of LMO3 suppresses the invasion and anoikis inhibition of HCC cells in vitro {#Sec19}
--------------------------------------------------------------------------------------

To investigate the biological functions of LMO3 in HCC, we detected the expression level of LMO3 in 9 HCC cell lines. As shown in Fig. [2a](#Fig2){ref-type="fig"}, we found that LMO3 had high expression levels in MHCC-97H and SMMC-7721 cells. Then we selected MHCC-97H and SMMC-7721 cells and knocked down LMO3 by using siRNA (labeled as si-LMO3--1 and si-LMO3--2). Through western blotting analyses, we found that LMO3 was successfully silenced in MHCC-97H (Fig. [2b](#Fig2){ref-type="fig"}) and SMMC-7721 cells (Fig. [2c](#Fig2){ref-type="fig"}).Fig. 2LMO3 knockdown suppresses the invasion and anoikis inhibition of HCC cells in vitro. **a** Expression of LMO3 in HCC cell lines, including HCCLM3, HepG2, Huh-7, MHCC-97H, MHCC-97 L, SK-Hep1, SMMC-7721, SNU-423 and SNU-449 cells. **b** and **c** The protein expression level of LMO3 in MHCC-97H (**b**) and SMMC-7721 (**c**) cells, which were infected with siRNA of LMO3 or NC. **d** Representative photos of invaded MHCC-97H cells infected with siRNA of LMO3 or NC. Statistical analysis of invaded MHCC-97H cells in the three groups is shown below. Scale bars: 10 μm. **e** Representative photos of invaded SMMC-7721 cells infected with siRNA of LMO3 or NC. Statistical analysis of invaded SMMC-7721 cells in the three groups is shown below. Scale bars: 10 μm. **f** Flow cytometry analysis of anoikis of MHCC-97H cells infected with siRNA of LMO3 or NC. Flow cytometry statistical analysis of apoptotic MHCC-97H cells in the two groups is shown below. **g** Flow cytometry analysis of anoikis of SMMC-7721 cells infected with siRNA of LMO3 or NC. Flow cytometry statistical analysis of apoptotic SMMC-7721 cells in the two groups is shown below. \*\**P* \< 0.01, NS, no significant

Then we investigated the role of LMO3 in the invasion of HCC cells. By transwell matrigel invasion assay, it was found that knockdown of LMO3 suppressed the invasiveness of MHCC-97H and SMMC-7721 (Fig. [2d, e](#Fig2){ref-type="fig"}) cells after 48 h. Furthermore, through annexin V anoikis assay, we found that the knockdown of LMO3 promoted the anoikis of MHCC-97H and SMMC-7721 (Fig. [2f](#Fig2){ref-type="fig"}, [g](#Fig2){ref-type="fig"}) cells after 48 h. Additionally, by Edu assay, we found that the proliferation of MHCC-97H and SMMC-7721 cells was not affected by LMO3 knockdown at 24-, 48- and 72-h time points respectively (Additional file [4](#MOESM4){ref-type="media"}: Figure S1a, b).

Knockdown of LMO3 suppresses the intrahepatic and distant metastasis of HCC in vivo {#Sec20}
-----------------------------------------------------------------------------------

To further investigate the role of LMO3 in cancer progression in vivo, sh-LMO3 and control cells (SMMC-7721) were orthotopically injected into nude mice to assess intrahepatic metastases and intravenously transplanted to assess distant metastases. After 6 weeks, we found that the intrahepatic metastatic nodules in the sh-LMO3 group were obviously less than in the vehicle group (Fig. [3a](#Fig3){ref-type="fig"}, [b](#Fig3){ref-type="fig"}). Mice survival in the LMO3-silenced group was significantly increased compared to the vehicle group (Fig. [3c](#Fig3){ref-type="fig"}). Histological staining of the liver tissues indicated that mice transplanted with sh-LMO3 cells had fewer intrahepatic metastatic nodules than those transplanted with control cells (Fig. [3d](#Fig3){ref-type="fig"}, [e](#Fig3){ref-type="fig"}). Meanwhile, the pulmonary metastatic nodules in mice transplanted with sh-LMO3 cells were less than those transplanted with control cells (Fig. [3f](#Fig3){ref-type="fig"}, [g](#Fig3){ref-type="fig"}).Fig. 3LMO3 knockdown suppresses the metastasis of HCC cells in vivo. **a** Representative photos of liver tissues from mice orthotopically inoculated with LMO3 silenced SMMC-7721 and control cells (*n* = 5 each group). **b** Statistical analysis of intrahepatic metastatic tumor volume is shown right. **c** Mice survival of LMO3 silenced SMMC-7721 and control group (*n* = 10 each group) (*P* \< 0.001). **d** Representative images of H&E staining in liver tissues from mice orthotopically inoculated with LMO3 silenced SMMC-7721 and control cells (*n* = 5 each group). Scale bars: 10 μm. **e** Statistical analysis of intrahepatic metastatic focis in the two groups is shown below. **f** Pulmonary metastases were detected by H&E staining (*n* = 6 each group). Scale bars: 10 μm. **g** Statistical analysis of numbers of pulmonary metastatic nodules is shown below. \*\**P* \< 0.01

LMO3 knockdown increases the phosphorylation of YAP/LATS1 signaling and decreases Rho GTPases activities {#Sec21}
--------------------------------------------------------------------------------------------------------

We further investigated the underlying mechanism of LMO3 in HCC. Through western blotting analyses, we found that the Hippo signaling pathway played important roles in HCC invasion and metastasis. Interestingly, knockdown of LMO3 in MHCC-97H or SMMC-7721 cells significantly increased the phosphorylation of YAP. Furthermore, the phosphorylation of LATS1, a core component of the Hippo pathway, was also increased by silencing LMO3 (Fig. [4a](#Fig4){ref-type="fig"}, [b](#Fig4){ref-type="fig"}). Then LMO3 knockdown and control MHCC-97H or SMMC-7721 cells were serum starved for 24 h. The activities of RhoA and Cdc42 were measured by pull-down assays. We found that RhoA and Cdc42 activities were suppressed by LMO3 knockdown. Rac1 activity had no obvious change in LMO3 knockdown and control MHCC-97H or SMMC-7721 cells (Fig. [4c](#Fig4){ref-type="fig"}, [d](#Fig4){ref-type="fig"}).Fig. 4Knockdown of LMO3 increases the phosphorylation of YAP/LATS1 and decreases Rho GTPases activities. **a** and **b** Western blotting analysis of phospho-YAP, YAP, phospho-LATS1 and LATS1 in LMO3 knockdown and control MHCC-97H (a) or SMMC-7721 cells (b). Statistical analyses of phospho-YAP/YAP and phospho-LATS1/LATS1 densitometry are shown below. **c** and **d** MHCC-97H (c) or SMMC-7721 (d) cells were serum starved for 24 h and the activities of RhoA, Cdc42 and Rac1 were measured by pull-down assays in LMO3 knockdown and control cells. Statistical analyses of active-RhoA/total-RhoA and active-Cdc42/total-Cdc42 densitometry are shown below. **e** The mRNA levels of CTGF, ANKRD1 and CYR61 in LMO3 knockdown and control MHCC-97H cells. \*\**P* \< 0.01. **f** Western blotting analysis of CTGF, ANKRD1 and CYR61 in LMO3 knockdown and control MHCC-97H cells

We also detected the mRNA levels of canonical YAP target genes, including Connective Tissue Growth Factor (CTGF), Ankyrin Repeat Domain 1 (ANKRD1), and Cysteine Rich Angiogenic Inducer 61 (CYR61). It was found that CTGF, ANKRD1 and CYR61 mRNA or protein levels were significantly suppressed in LMO3-silenced MHCC-97H cells (Fig. [4e](#Fig4){ref-type="fig"}). These results suggested that the Hippo pathway was activated in LMO3-silenced HCC cells.

LMO3 directly interacts with LATS1, and recombinant LMO3 protein administration decreases the phosphorylation of YAP/LATS1 signaling and increases Rho GTPases activities {#Sec22}
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Co-immunoprecipitation experiments were performed to investigate whether LMO3 was directly associated with the components of the Hippo pathway. First, Huh-7 was transfected with HA-tagged LMO3 or vector control. We found that immunoprecipitates of LMO3 from Huh-7 cells contained LATS1, but no YAP (Fig. [5a](#Fig5){ref-type="fig"}). Furthermore, we added recombinant LMO3 (rLMO3) protein into Huh-7 cells, in which LMO3 had a low expression level. The results showed that the phosphorylation of YAP or LATS1 was significantly suppressed after treatment with rLMO3 protein (Fig. [5b, c](#Fig5){ref-type="fig"}). Additionally, RhoA and Cdc42 activities were increased by rLMO3 protein administration, while Rac1 activity had no obvious change (Fig. [5d](#Fig5){ref-type="fig"}, [e](#Fig5){ref-type="fig"}).Fig. 5LMO3 directly interacts with LATS1, and recombinant LMO3 protein administration suppresses the phosphorylation of YAP/LATS1 and increases Rho GTPases activities. **a** Co-immunoprecipitation of LMO3 with LATS1 or YAP. Huh-7 cell lysates transfected with HA-tagged LMO3 or vector control were subjected to immunoprecipitation with anti-HA monoclonal antibody or control IgG, followed by immunoblotting with anti-LATS1 or YAP antibodies. The input control on the right panel shows the levels of transfected HA-LMO3 and LATS1 or YAP in HA-tagged LMO3 or vector control transfected cells. **b** and **c** Western blotting analysis of phospho-YAP, YAP, phospho-LATS1 and LATS1 in recombinant LMO3 (rLMO3) protein treated and control Huh-7 cells (**b**). Statistical analyses of phospho-YAP/YAP and phospho-LATS1/LATS1 densitometry are shown right (**c**). **d** and **e** Huh-7 cells were serum starved for 24 h and the activities of RhoA and Cdc42 were measured by pull-down assays in rLMO3 protein treated and control cells (**d**). Statistical analyses of active-RhoA/total-RhoA and active-Cdc42/total-Cdc42 densitometry are shown right (**e**). **f** The mRNA levels of CTGF, ANKRD1 and CYR61 in rLMO3 protein treated and control Huh-7 cells. \**P* \< 0.05, \*\**P* \< 0.01. **g** Western blotting analysis of CTGF, ANKRD1 and CYR61 in rLMO3 protein treated and control Huh-7 cells

Meanwhile, we also found that CTGF, ANKRD1 and CYR61 mRNA or protein levels were significantly increased in rLMO3 protein treated Huh-7 cells (Fig. [5f](#Fig5){ref-type="fig"}). Thus, we conclude that LMO3 interacts with LATS1, increases Rho GTPases activities and suppresses the Hippo signaling pathway.

Hippo pathway inhibitors could abrogate recombinant LMO3 protein-induced HCC cell invasion and anoikis inhibiton {#Sec23}
----------------------------------------------------------------------------------------------------------------

By using Verteporfin (the inhibitor of YAP-TEAD) and Peptide 17 (YAP-TEAD inhibitor I, the inhibitor of YAP-TEAD), we further investigated the effects of LMO3 on HCC cell invasion and anoikis inhibition. rLMO3 protein was added into Huh-7 and SNU-423 cells, in which LMO3 had low expression levels. Then, Verteporfin and Peptide 17 were added after 2 h. We found that Verteporfin and Peptide 17 abrogated rLMO3 protein-induced Huh-7 or SNU-423 cell invasion (Fig. [6a](#Fig6){ref-type="fig"}, [b](#Fig6){ref-type="fig"}). Meanwhile, the anoikis inhibition of Huh-7 or SNU-423 cells induced by rLMO3 protein was also abrogated by these inhibitors (Fig. [6c](#Fig6){ref-type="fig"}, [d](#Fig6){ref-type="fig"}).Fig. 6Hippo pathway inhibitors abrogate recombinant LMO3 protein induced HCC cell invasion and anoikis inhibiton. **a** and **b** Huh-7 and SNU-423 cells were treated with 50 nM rLMO3 protein, 50 nM rLMO3 protein plus 50 nM Verteporfin (the inhibitor of YAP-TEAD), 50 nM rLMO3 protein plus 50 nM Peptide 17 (the inhibitor of YAP-TEAD) respectively. The invaded Huh-7 (**a**) and SNU-423 (**b**) cells were analyzed after 48 h. Scale bars: 10 μm. **c** and d Huh-7 and SNU-423 cells were treated with 50 nM rLMO3 protein, 50 nM rLMO3 protein plus 50 nM Verteporfin, 50 nM rLMO3 protein plus 50 nM Peptide 17 respectively. The apoptotic Huh-7 (**c**) and SNU-423 (**d**) cells were analyzed after 48 h. \**P* \< 0.05, \*\**P* \< 0.01. **e** LMO3 promoted HCC cell invasion and anoikis inhibition by interacting with LATS1 and suppressing Hippo signaling

These results indicate that LMO3 promoted HCC cell invasion and anoikis inhibition by interacting with LATS1 and suppressing Hippo signaling (Fig. [6e](#Fig6){ref-type="fig"}).

Discussion {#Sec24}
==========

In recent years, studies on LMO3 in some types of cancers have been reported \[[@CR14]--[@CR17]\]. Nevertheless, the detailed biological functions and related mechanism of LMO3 in HCC were first investigated in this research. We found that LMO3 expression was closely related with tumor metastasis related clinicopathological findings and patient prognoses. Our experiments in vitro and in vivo revealed that knockdown of LMO3 suppresses cell invasion and anoikis inhibition in HCC. All of the above data suggested that LMO3 is involved in the invasion, metastasis and anoikis inhibition of HCC cells.

Invasion and metastasis are major concerns during the progression of cancer \[[@CR19]--[@CR23]\]. The Hippo pathway is known to be pivotal in modulating the invasion and metastasis of tumor cells \[[@CR24]--[@CR27]\]. YAP is known to contribute to metastasis via multiple mechanisms. YAP interacts with TEAD and FOS in the nucleus, and reprograms gene expression to induce epithelial-mesenchymal transition (EMT). YAP also antagonizes E-cadherin junction assembly by regulating actin cytoskeleton organization and contributes to EMT. Furthermore, YAP activation supports stiffening of the extracellular matrix of cancer-associated fibroblasts (CAFs) to enhance YAP nuclear localization in tumor cells. Such interplay between cancer cells and CAFs might amplify the effects of YAP during tumorigenesis \[[@CR28]--[@CR31]\].

LMO3 has been proved to promote cell invasion or proliferation through Akt-mTOR/GSK3β signaling in gastric cancer \[[@CR32]\]. In this research, we found that knockdown of LMO3 increased the phosphorylation of YAP and LATS1, and thus restrained them in the cytoplasm where they lost their transcriptional activation. Furthermore, these results were confirmed by detecting Rho GTPases activities and canonical YAP target genes. Meanwhile, administration of rLMO3 protein led to an opposite effect of LMO3 in the Hippo pathway.

The studies of Aoyama et al. and Isogai et al. showed that LMO3 interacts with HEN2 and enhances cell growth in neuroblastoma \[[@CR14], [@CR15]\]. Interestingly, in this research we found that LMO3 directly interacts with LATS1, and thus it suppressed Hippo signaling. Identifying the interaction between LMO3 and LATS1 provides direct evidence for the important role of LMO3 in the regulation of Hippo signaling. Also, we found that rLMO3 protein-induced HCC cell invasion and anoikis inhibition is abrogated by the inhibitors of the Hippo pathway, indicating that LMO3-induced HCC cell invasion, metastasis and anoikis inhibition are dependent on the suppression of Hippo signaling.

Conclusions {#Sec25}
===========

In conclusion, we found that LMO3 plays an important role in HCC cell invasion, metastasis and anoikis inhibition. High expression levels of LMO3 in HCC suppresses the Hippo signaling pathway by interacting with LATS1, and thus LMO3 promotes the invasion and metastasis of HCC cells. LMO3 may be used as a potential therapeutic strategy for HCC in future.

Additional files
================

 {#Sec26}

Additional file 1:**Table S1** Primer sequences used for human LMO3, CTGF, ANKRD1 and CYR61 detection. **a** Edu assay of MHCC-97H cells infected with siRNA of LMO3 at 0, 24, 48 and 72 h time points respectively. **b** Edu assay of SMMC-7721 cells infected with siRNA of LMO3 at 0, 24, 48 and 72 h time points respectively. \*\**P* \< 0.01. (DOC 30 kb) Additional file 2:**Figure S2** The structure of pGreenPuro used for shRNA and vector construction. (PDF 622 kb) Additional file 3:**Table S2** The original data of tissue microarray assay. (DOC 468 kb) Additional file 4:**Figure S1** LMO3 knockdown has no effects on the proliferation of HCC cells. Multiplicity: 1 -- single, 2 - multiple; Satelite: 0 -- no, 1 or 2 - yes; Encapsulation: 0 -- complete, 1 - incomplete; Vascular invasion: 0 -- no, 1 - yes; Tumor thrombus: 0 -- no, 1 - yes. (PDF 505 kb)

ANKRD1

:   Ankyrin Repeat Domain 1

CNL

:   Corresponding non-cancerous liver

CTGF

:   Connective Tissue Growth Factor

CYR61

:   Cysteine Rich Angiogenic Inducer 61

DFS

:   Disease-free survival

HCC

:   Hepatocellular carcinoma

LATS1

:   Large Tumor Suppressor Kinase 1

LMO3

:   LIM domain only 3

OS

:   Overall survival

rLMO3

:   recombinant LMO3

YAP

:   Yes Associated Protein
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